BioAtla, Inc. (BCAB)
OTC Markets
Key stats Fiscal year 2025
Income statement
- Net income
- -59,607,000
- Operating income
- -59,305,000
- Earnings per share
- -1.01
- R&D expense
- 43,573,000
Growth and profitability
- Return on assets
- -431.06
Balance sheet
- Total assets
- 13,828,000
- Total liabilities
- 50,017,000
- Shareholders' equity
- -36,189,000
- Cash and equivalents
- 7,118,000
- Current ratio
- 0.37
Cash flow and ratios
- Operating cash flow
- -48,204,000
Shareholder returns
- Shares outstanding
- 32,315,301
Company information
- Headquarters
- San Diego, CA
- Exchange
- OTC Markets
- Fiscal year end
- 12-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
BioAtla, Inc. trades on OTC Markets under the ticker symbol BCAB. This page brings together its price chart, company profile, key financial figures and technical indicators.